How Does Early Detection of Lung Cancer Improve Your Survival?
The Importance of Early Detection
Lung cancer is the leading cause of cancer-related deaths worldwide, but early detection and treatment can significantly improve survival rates. When lung cancer is caught in its earliest stages, treatment options are more effective, survival rates increase, and the overall burden on patients is reduced.
Understanding the different types of lung cancer and how they progress highlights the critical need for early diagnosis—especially for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), the two most common forms of lung cancer.
How Early Detection Impacts Survival Rates
Types of Lung Cancer
Non-Small Cell Lung Cancer (NSCLC)
NSCLC accounts for approximately 80–85% of all lung cancer cases and typically grows more slowly than SCLC. When detected early, NSCLC can often be treated successfully with surgery and other targeted therapies.
Stage I and II: If detected early, NSCLC has a 5-year survival rate of 60–80%.
Stage III: As the cancer spreads to nearby lymph nodes, the 5-year survival rate drops to 15–30%.
Stage IV: Once NSCLC has metastasized to other organs, the 5-year survival rate falls to about 2–6%.
Small Cell Lung Cancer (SCLC)
SCLC is more aggressive than NSCLC, often spreading quickly before symptoms appear. This makes early detection even more critical.
Limited stage (confined to one lung or nearby lymph nodes): The 5-year survival rate is around 25–30%.
Extensive stage (spread beyond the lung): The 5-year survival rate is less than 5%.
The Benefits of Early Detection
Detecting lung cancer at an early stage provides several advantages:
Higher Survival Rates: Patients diagnosed before the cancer spreads to other parts of the body have significantly better outcomes.
More Treatment Options: Surgery, targeted therapies, and immunotherapy are more effective when the disease is caught early.
Lower Treatment Costs: Late-stage cancer treatments, such as extensive chemotherapy and palliative care, are often more expensive and have a lower success rate.
The CIZ1B Biomarker Test – A Breakthrough in Early Detection
At Cizzle Bio, we are committed to advancing early detection of lung cancer. Our innovative CIZ1B Biomarker Testis a simple blood test designed to detect lung cancer at its earliest stages—before symptoms appear, when treatment is most effective.
If you are at a higher risk of developing lung cancer, talk to your doctor about screening. Those at higher risk include:
Adults aged 50 or older
Individuals with a 20 pack-year history of smoking or significant secondhand smoke exposure
People who currently smoke or quit within the past 15 years
Those with environmental or occupational exposure to toxins (including military service-related exposures)
Individuals with exposure to radiation/radon
A family history of lung cancer, which may suggest a genetic risk but is often linked to environmental factors.
Early detection saves lives. The CIZ1B biomarker-based blood test is revolutionizing lung cancer care—offering hope, improved outcomes, and a greater chance of survival.
Sources
American Cancer Society. Lung Cancer Survival Rates. Available at: https://www.cancer.org/cancer/types/lung-cancer/detection-diagnosis-staging/survival-rates.html
National Library of Medicine. Small Cell Lung Cancer Prognosis. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482458/#:~:text=If
American Lung Association. State of Lung Cancer Report. Available at: https://www.lung.org/research/state-of-lung-cancer/key-findings
American Lung Association. Palliative Care for Lung Cancer. Available at: https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/treatment/types-of-treatment/supportive-palliative-care
National Cancer Institute. Smoking and Cancer Risk. Available at: https://www.cancer.gov/about-cancer/causes-prevention/risk/tobacco/cessation-fact-sheet
